Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are used in the treatment of type 2 diabetes. Available sub‐group analysis of clinical trials does not allow a clear identification of predictors of therapeutic response to these drugs. The aim of this study is the assessment of predictors of response to DPP‐4 inhibitors. Materials and methods: A meta‐analysis was performed, exploring correlation between 24‐week effects on HbA 1c of maximal doses of DPP‐4 inhibitors, compared either with placebo or with other active drugs, matches to baseline characteristics of patients enrolled in 63 randomized clinical trials, either published or unpublished but disclosed on different websites were studied. Results: DPP‐4 inhibitors significantly reduce HbA 1c at 24 weeks [by 0.6 (0.5–0.7)%] when compared with placebo; no difference in HbA 1c was observed in comparisons with thiazolidinediones and α‐glucosidase inhibitors, whereas sulfonylureas and metformin produced a greater reduction of HbA 1c, at least in the short term. DPP‐4 inhibitors produced a smaller weight gain than thiazolidinediones, and showed a lower hypoglycaemia risk than sulfonylureas. The placebo‐subtracted effect of DPP‐4 inhibitors on HbA 1c was greater in older patients and in those with lower fasting plasma glucose at baseline. Similar results were obtained in comparisons with thiazolidinediones and metformin. Conclusions: Although drugs for type 2 diabetes are studied in heterogeneous samples of patients, their efficacy can be predicted by some clinical parameters. DPP‐4 inhibitors appear to be more effective in older patients with mild/moderate fasting hyperglycaemia. These data could be useful for a better definition of the profile of patients who are likely to benefit most from these drugs. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282 · cited 1×
“However, because these tests have low statistical power when the number of trials is small [10], undetected bias may still be present.”
BackgroundCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 1×
“Vildagliptin versus Placebo Garber [11] 132/144 24 58 18–80 7 Garber [12] 138/138 24 54 18–80 5 Fonseca [13] 144/152 24 59 18–80 15 Rosenstock [14] 148/161 24 51 18–80 2 Pi-Sunyer [15] 174/92 24 51 18–80 2 Bosi [16] 185/182 24 54 18–78 6 Goodman [17] 248/122 24 55 18–78 NR CLAF237ADE0214 268/127 24 61 18–85 NR Dejager…”
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · cited 1×
“The modest difference in endpoint BMI between DPP-4 inhibitors and placebo, which had been described previously [45], can be easily explained by the improvement of metabolic control and the consequent reduction of glycosuria.”
BackgroundRosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · cited 1×
“Vildagliptin versus Placebo Garber [11] 132/144 24 58 18–80 7 Garber [12] 138/138 24 54 18–80 5 Fonseca [13] 144/152 24 59 18–80 15 Rosenstock [14] 148/161 24 51 18–80 2 Pi-Sunyer [15] 174/92 24 51 18–80 2 Bosi [16] 185/182 24 54 18–78 6 Goodman [17] 248/122 24 55 18–78 NR CLAF237ADE0214 268/127 24 61 18–85 NR Dejager…”
Cited by
Subclinical hypothyroidism and type 2 diabetes: A systematic review and meta-analysis
Han, C., He, X., Xia, X., Li, Y., Shi, X., Shan, Z., & Teng, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135233 · Cited by 258
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Heymsfield, S. B., Raji, A., Gallo, S., Liu, J., Pong, A., Hannachi, H., & Terra, S. G. (2020) · Obesity · doi:10.1002/oby.22748 · Cited by 21
Metadata
- Authors
- Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2011-05
- Volume
- 27
- Issue
- 4
- Pages
- 362-372
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2019470196
- Cited by
- 69
- References
- 7
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.